Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world study

BACKGROUND: There are few real-world studies in which the efficacy of sequential crizotinib and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are compared with direct therapy of second-generation ALK TKI in ALK-positive advanced lung cancer. METHODS: Between Ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jingwen, Zhou, Huan, Song, Zhengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267910/
https://www.ncbi.nlm.nih.gov/pubmed/37324060
http://dx.doi.org/10.21037/jtd-22-1783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267910/
https://www.ncbi.nlm.nih.gov/pubmed/37324060
http://dx.doi.org/10.21037/jtd-22-1783

Ejemplares similares